Gastrointestinal Drugs-United States Market Status and Trend Report 2013-2023
Report Summary
Gastrointestinal Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Gastrointestinal Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Gastrointestinal Drugs 2013-2017, and development forecast 2018-2023
Main market players of Gastrointestinal Drugs in United States, with company and product introduction, position in the Gastrointestinal Drugs market
Market status and development trend of Gastrointestinal Drugs by types and applications
Cost and profit status of Gastrointestinal Drugs, and marketing status
Market growth drivers and challenges
The report segments the United States Gastrointestinal Drugs market as:
United States Gastrointestinal Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Gastrointestinal Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Acid Neutralizers
Antidiarrheal and Laxatives
Antiemetic and Antinauseants
Anti-inflammatory Drugs
Biologics
Others
United States Gastrointestinal Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
United States Gastrointestinal Drugs Market: Players Segment Analysis (Company and Product introduction, Gastrointestinal Drugs Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
Allergan
AstraZeneca
Bayer
Boehringer Ingelheim
GlaxoSmithKline
Janssen Biotech
Sanofi
Takeda Pharmaceutical
Valeant Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Gastrointestinal Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Gastrointestinal Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Gastrointestinal Drugs 2013-2017, and development forecast 2018-2023
Main market players of Gastrointestinal Drugs in United States, with company and product introduction, position in the Gastrointestinal Drugs market
Market status and development trend of Gastrointestinal Drugs by types and applications
Cost and profit status of Gastrointestinal Drugs, and marketing status
Market growth drivers and challenges
The report segments the United States Gastrointestinal Drugs market as:
United States Gastrointestinal Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Gastrointestinal Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Acid Neutralizers
Antidiarrheal and Laxatives
Antiemetic and Antinauseants
Anti-inflammatory Drugs
Biologics
Others
United States Gastrointestinal Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
United States Gastrointestinal Drugs Market: Players Segment Analysis (Company and Product introduction, Gastrointestinal Drugs Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
Allergan
AstraZeneca
Bayer
Boehringer Ingelheim
GlaxoSmithKline
Janssen Biotech
Sanofi
Takeda Pharmaceutical
Valeant Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS
1.1 Definition of Chronic Idiopathic Constipation Drugs in This Report
1.2 Commercial Types of Chronic Idiopathic Constipation Drugs
1.2.1 Linaclotide
1.2.2 Lubiprostone
1.2.3 Other
1.3 Downstream Application of Chronic Idiopathic Constipation Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of Chronic Idiopathic Constipation Drugs
1.5 Market Status and Trend of Chronic Idiopathic Constipation Drugs 2013-2023
1.5.1 Global Chronic Idiopathic Constipation Drugs Market Status and Trend 2013-2023
1.5.2 Regional Chronic Idiopathic Constipation Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Chronic Idiopathic Constipation Drugs 2013-2017
2.2 Production Market of Chronic Idiopathic Constipation Drugs by Regions
2.2.1 Production Volume of Chronic Idiopathic Constipation Drugs by Regions
2.2.2 Production Value of Chronic Idiopathic Constipation Drugs by Regions
2.3 Demand Market of Chronic Idiopathic Constipation Drugs by Regions
2.4 Production and Demand Status of Chronic Idiopathic Constipation Drugs by Regions
2.4.1 Production and Demand Status of Chronic Idiopathic Constipation Drugs by Regions 2013-2017
2.4.2 Import and Export Status of Chronic Idiopathic Constipation Drugs by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Chronic Idiopathic Constipation Drugs by Types
3.2 Production Value of Chronic Idiopathic Constipation Drugs by Types
3.3 Market Forecast of Chronic Idiopathic Constipation Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Chronic Idiopathic Constipation Drugs by Downstream Industry
4.2 Market Forecast of Chronic Idiopathic Constipation Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Chronic Idiopathic Constipation Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 CHRONIC IDIOPATHIC CONSTIPATION DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Chronic Idiopathic Constipation Drugs by Major Manufacturers
6.2 Production Value of Chronic Idiopathic Constipation Drugs by Major Manufacturers
6.3 Basic Information of Chronic Idiopathic Constipation Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Chronic Idiopathic Constipation Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Chronic Idiopathic Constipation Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 CHRONIC IDIOPATHIC CONSTIPATION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Pfizer
7.1.1 Company profile
7.1.2 Representative Chronic Idiopathic Constipation Drugs Product
7.1.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Glaxosmithkline
7.2.1 Company profile
7.2.2 Representative Chronic Idiopathic Constipation Drugs Product
7.2.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Glaxosmithkline
7.3 Roche Holding AG
7.3.1 Company profile
7.3.2 Representative Chronic Idiopathic Constipation Drugs Product
7.3.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Roche Holding AG
7.4 Sanofi
7.4.1 Company profile
7.4.2 Representative Chronic Idiopathic Constipation Drugs Product
7.4.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.5 Bayer AG
7.5.1 Company profile
7.5.2 Representative Chronic Idiopathic Constipation Drugs Product
7.5.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
7.6 Merck
7.6.1 Company profile
7.6.2 Representative Chronic Idiopathic Constipation Drugs Product
7.6.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Merck
7.7 Eli Lilly
7.7.1 Company profile
7.7.2 Representative Chronic Idiopathic Constipation Drugs Product
7.7.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
7.8 Allergens
7.8.1 Company profile
7.8.2 Representative Chronic Idiopathic Constipation Drugs Product
7.8.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Allergens
7.9 Chugai Pharmaceutical
7.9.1 Company profile
7.9.2 Representative Chronic Idiopathic Constipation Drugs Product
7.9.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Chugai Pharmaceutical
7.10 Ferring International Center S.A
7.10.1 Company profile
7.10.2 Representative Chronic Idiopathic Constipation Drugs Product
7.10.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Ferring International Center S.A
7.11 Synergy Pharmaceuticals
7.11.1 Company profile
7.11.2 Representative Chronic Idiopathic Constipation Drugs Product
7.11.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals
7.12 Salix Pharmaceuticals Ltd
7.12.1 Company profile
7.12.2 Representative Chronic Idiopathic Constipation Drugs Product
7.12.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
7.13 Sucampo Pharmaceuticals Inc
7.13.1 Company profile
7.13.2 Representative Chronic Idiopathic Constipation Drugs Product
7.13.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals Inc
7.14 Ironwood Pharmaceuticals Inc
7.14.1 Company profile
7.14.2 Representative Chronic Idiopathic Constipation Drugs Product
7.14.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals Inc
7.15 Valeant Pharmaceuticals International
7.15.1 Company profile
7.15.2 Representative Chronic Idiopathic Constipation Drugs Product
7.15.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International
7.16 Daiichi Sankyo
7.17 Cosmo Pharmaceuticals SA
7.18 Progenics Pharmaceuticals Inc
7.19 Theravance Biopharma Inc
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS
8.1 Industry Chain of Chronic Idiopathic Constipation Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS
9.1 Cost Structure Analysis of Chronic Idiopathic Constipation Drugs
9.2 Raw Materials Cost Analysis of Chronic Idiopathic Constipation Drugs
9.3 Labor Cost Analysis of Chronic Idiopathic Constipation Drugs
9.4 Manufacturing Expenses Analysis of Chronic Idiopathic Constipation Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Chronic Idiopathic Constipation Drugs in This Report
1.2 Commercial Types of Chronic Idiopathic Constipation Drugs
1.2.1 Linaclotide
1.2.2 Lubiprostone
1.2.3 Other
1.3 Downstream Application of Chronic Idiopathic Constipation Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of Chronic Idiopathic Constipation Drugs
1.5 Market Status and Trend of Chronic Idiopathic Constipation Drugs 2013-2023
1.5.1 Global Chronic Idiopathic Constipation Drugs Market Status and Trend 2013-2023
1.5.2 Regional Chronic Idiopathic Constipation Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Chronic Idiopathic Constipation Drugs 2013-2017
2.2 Production Market of Chronic Idiopathic Constipation Drugs by Regions
2.2.1 Production Volume of Chronic Idiopathic Constipation Drugs by Regions
2.2.2 Production Value of Chronic Idiopathic Constipation Drugs by Regions
2.3 Demand Market of Chronic Idiopathic Constipation Drugs by Regions
2.4 Production and Demand Status of Chronic Idiopathic Constipation Drugs by Regions
2.4.1 Production and Demand Status of Chronic Idiopathic Constipation Drugs by Regions 2013-2017
2.4.2 Import and Export Status of Chronic Idiopathic Constipation Drugs by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Chronic Idiopathic Constipation Drugs by Types
3.2 Production Value of Chronic Idiopathic Constipation Drugs by Types
3.3 Market Forecast of Chronic Idiopathic Constipation Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Chronic Idiopathic Constipation Drugs by Downstream Industry
4.2 Market Forecast of Chronic Idiopathic Constipation Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Chronic Idiopathic Constipation Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 CHRONIC IDIOPATHIC CONSTIPATION DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Chronic Idiopathic Constipation Drugs by Major Manufacturers
6.2 Production Value of Chronic Idiopathic Constipation Drugs by Major Manufacturers
6.3 Basic Information of Chronic Idiopathic Constipation Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Chronic Idiopathic Constipation Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Chronic Idiopathic Constipation Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 CHRONIC IDIOPATHIC CONSTIPATION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Pfizer
7.1.1 Company profile
7.1.2 Representative Chronic Idiopathic Constipation Drugs Product
7.1.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Glaxosmithkline
7.2.1 Company profile
7.2.2 Representative Chronic Idiopathic Constipation Drugs Product
7.2.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Glaxosmithkline
7.3 Roche Holding AG
7.3.1 Company profile
7.3.2 Representative Chronic Idiopathic Constipation Drugs Product
7.3.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Roche Holding AG
7.4 Sanofi
7.4.1 Company profile
7.4.2 Representative Chronic Idiopathic Constipation Drugs Product
7.4.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.5 Bayer AG
7.5.1 Company profile
7.5.2 Representative Chronic Idiopathic Constipation Drugs Product
7.5.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
7.6 Merck
7.6.1 Company profile
7.6.2 Representative Chronic Idiopathic Constipation Drugs Product
7.6.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Merck
7.7 Eli Lilly
7.7.1 Company profile
7.7.2 Representative Chronic Idiopathic Constipation Drugs Product
7.7.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
7.8 Allergens
7.8.1 Company profile
7.8.2 Representative Chronic Idiopathic Constipation Drugs Product
7.8.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Allergens
7.9 Chugai Pharmaceutical
7.9.1 Company profile
7.9.2 Representative Chronic Idiopathic Constipation Drugs Product
7.9.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Chugai Pharmaceutical
7.10 Ferring International Center S.A
7.10.1 Company profile
7.10.2 Representative Chronic Idiopathic Constipation Drugs Product
7.10.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Ferring International Center S.A
7.11 Synergy Pharmaceuticals
7.11.1 Company profile
7.11.2 Representative Chronic Idiopathic Constipation Drugs Product
7.11.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals
7.12 Salix Pharmaceuticals Ltd
7.12.1 Company profile
7.12.2 Representative Chronic Idiopathic Constipation Drugs Product
7.12.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
7.13 Sucampo Pharmaceuticals Inc
7.13.1 Company profile
7.13.2 Representative Chronic Idiopathic Constipation Drugs Product
7.13.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals Inc
7.14 Ironwood Pharmaceuticals Inc
7.14.1 Company profile
7.14.2 Representative Chronic Idiopathic Constipation Drugs Product
7.14.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals Inc
7.15 Valeant Pharmaceuticals International
7.15.1 Company profile
7.15.2 Representative Chronic Idiopathic Constipation Drugs Product
7.15.3 Chronic Idiopathic Constipation Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International
7.16 Daiichi Sankyo
7.17 Cosmo Pharmaceuticals SA
7.18 Progenics Pharmaceuticals Inc
7.19 Theravance Biopharma Inc
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS
8.1 Industry Chain of Chronic Idiopathic Constipation Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS
9.1 Cost Structure Analysis of Chronic Idiopathic Constipation Drugs
9.2 Raw Materials Cost Analysis of Chronic Idiopathic Constipation Drugs
9.3 Labor Cost Analysis of Chronic Idiopathic Constipation Drugs
9.4 Manufacturing Expenses Analysis of Chronic Idiopathic Constipation Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF CHRONIC IDIOPATHIC CONSTIPATION DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
